Bromopyruvic acid

Bromopyruvic acid attracts attention in the biomedical research capacity through its potential to inhibit tyrosine phosphatases. Activity of such phosphatases is required for the activation of platelets, especially in a process called venous thromboembolism, a major cause of mortality during gastrointestinal cancer. Bromopyruvic-mediated inhibition of tyrosine phosphatases can counteract such thromboembolism and is investigated as novel angel to combat cancer-associated mortality. ^[2] The pyruvate transporter system can be used to deliver bromopyruvate inside trypanosomal cells. Once intracellular, the primary target of 3BP is glyceraldehyde-3-phosphate dehydrogenase, which is highly sensitive to inhibition by bromopyruvate.^[3] The pyruvate transporter system, which is known to be overexpressed in cancer cells, was later identified to be a monocarboxylate transporter called monocarboxylate transporter 1.^[4]